Abstract
Smoking and interleukin-6 (IL-6) are major factors in inflammation. The aim of this study was to investigate whether or not the IL6 −634C/G polymorphism (rs1800796) and its interaction with smoking influence serum C-reactive protein (CRP) concentrations. The subjects were 347 Japanese male employees of a transit company. CRP and conventional cardiovascular risk factors were evaluated. IL6 −634C/G polymorphisms were genotyped by allelic discrimination using fluorogenic probes and the 5′ nuclease assay. The mean values of CRP were significantly higher in current smokers than in nonsmokers after adjustment for age, body mass index (BMI), systolic blood pressure, total cholesterol, log triglycerides, high-density lipoprotein cholesterol (HDL-C), fasting glucose, and drinking habit (p=0.011). Comparison of three genotypes revealed significant interaction between smoking and the IL6 −634C/G genotype manifested by CRP concentrations (p=0.007) after the adjustments cited above. After stratification by smoking status, CRP differed significantly among IL6 −634C/G genotypes groups in nonsmokers (p=0.010, p for trend=0.007), whereas no significant difference was found in current smokers. Comparison between −634C/C and C/G+G/G groups revealed also a significant interaction between smoking and the IL6 −634C/G genotype (p=0.007). These findings suggest that the impact of the −634G allele on CRP elevation is greater in nonsmokers than in current smokers. Since gene-environment interactions have been insufficiently examined, further studies are required to clarify their effect on inflammation, including CRP elevation.
Similar content being viewed by others
Article PDF
References
Ross R : Atherosclerosis—an inflammatory disease. N Engl J Med 1999; 340: 115–126.
Ridker PM, Hennekens CH, Buring JE, Rifai N : C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836–843.
Koenig W, Sund M, Frohlich M, et al: C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99: 237–242.
Danesh J, Whincup P, Walker M, et al: Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000; 321: 199–204.
Ridker PM, Rifai N, Rose L, Buring JE, Cook NR : Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557–1565.
Heinrich PC, Castell JV, Andus T : Interleukin-6 and the acute phase response. Biochem J 1990; 265: 621–636.
Mendall MA, Patel P, Asante M, et al: Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease. Heart 1997; 78: 273–277.
Bermudez EA, Rifai N, Buring J, Manson JE, Ridker PM : Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women. Arterioscler Thromb Vasc Biol 2002; 22: 1668–1673.
Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB, European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group: Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 1997; 349: 462–466.
Vickers MA, Green FR, Terry C, et al: Genotype at a promoter polymorphism of the interleukin-6 gene is associated with baseline levels of plasma C-reactive protein. Cardiovasc Res 2002; 53: 1029–1034.
Latkovskis G, Licis N, Kalnins U : C-reactive protein levels and common polymorphisms of the interleukin-1 gene cluster and interleukin-6 gene in patients with coronary heart disease. Eur J Immunogenet 2004; 31: 207–213.
Libra M, Signorelli SS, Bevelacqua Y, et al: Analysis of G(−174)C IL-6 polymorphism and plasma concentrations of inflammatory markers in patients with type 2 diabetes and peripheral arterial disease. J Clin Pathol 2006; 59: 211–215.
Ortlepp JR, Metrikat J, Vesper K, et al: The interleukin-6 promoter polymorphism is associated with elevated leukocyte, lymphocyte, and monocyte counts and reduced physical fitness in young healthy smokers. J Mol Med 2003; 81: 578–584.
Saijo Y, Sata F, Yamada H, Kondo T, Kato EH, Kishi R : Single nucleotide polymorphisms in the promoter region of the interleukin-6 gene and the risk of recurrent pregnancy loss in Japanese women. Fertil Steril 2004; 81: 374–378.
Hayakawa T, Takamura T, Hisada A, Abe T, Nomura G, Kobayashi K : IL-6 gene polymorphism −174G/C does not contribute substantially to hyperlipidaemia and type II diabetes mellitus in Japanese men. Diabetologia 2002; 45: 453–454.
Zhai R, Liu G, Yang C, Huang C, Wu C, Christiani DC : The G to C polymorphism at −174 of the interleukin-6 gene is rare in a Southern Chinese population. Pharmacogenetics 2001; 11: 699–701.
Lim CS, Zheng S, Kim YS, et al: The −174 G to C polymorphism of interleukin-6 gene is very rare in Koreans. Cytokine 2002; 19: 52–54.
Ota N, Nakajima T, Nakazawa I, et al: A nucleotide variant in the promoter region of the interleukin-6 gene associated with decreased bone mineral density. J Hum Genet 2001; 46: 267–272.
Kitamura A, Hasegawa G, Obayashi H, et al: Interleukin-6 polymorphism (−634C/G) in the promotor region and the progression of diabetic nephropathy in type 2 diabetes. Diabet Med 2002; 19: 1000–1005.
Saijo Y, Sata F, Yamada H, et al: Ah receptor, CYP1A1, CYP1A2 and CYP1B1 gene polymorphisms are not involved in the risk of recurrent pregnancy loss. Mol Hum Reprod 2004; 10: 729–733.
Makhseed M, Raghupathy R, Azizieh F, Farhat R, Hassan N, Bandar A : Circulating cytokines and CD30 in normal human pregnancy and recurrent spontaneous abortions. Hum Reprod 2000; 15: 2011–2017.
Ferrari SL, Ahn-Luong L, Garnero P, Humphries SE, Greenspan SL : Two promoter polymorphisms regulating interleukin-6 gene expression are associated with circulating levels of C-reactive protein and markers of bone resorption in postmenopausal women. J Clin Endocrinol Metab 2003; 88: 255–259.
Hamid YH, Rose CS, Urhammer SA, et al: Variations of the interleukin-6 promoter are associated with features of the metabolic syndrome in Caucasian Danes. Diabetologia 2005; 48: 251–260.
Muller-Steinhardt M, Fricke L, Muller B, Ebel B, Kirchner H, Hartel C : Cooperative influence of the interleukin-6 promoter polymorphisms −597, −572 and −174 on long-term kidney allograft survival. Am J Transplant 2004; 4: 402–406.
Rivera-Chavez FA, Peters-Hybki DL, Barber RC, O'Keefe GE : Interleukin-6 promoter haplotypes and interleukin-6 cytokine responses. Shock 2003; 20: 218–223.
Fishman D, Faulds G, Jeffery R, et al: The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998; 102: 1369–1376.
Terry CF, Loukaci V, Green FR : Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem 2000; 275: 18138–18144.
Tanaka C, Mannami T, Kamide K, et al: Single nucleotide polymorphisms in the interleukin-6 gene associated with blood pressure and atherosclerosis in a Japanese general population. Hypertens Res 2005; 28: 35–41.
Saarikoski ST, Voho A, Reinikainen M, et al: Combined effect of polymorphic GST genes on individual susceptibility to lung cancer. Int J Cancer 1998; 77: 516–521.
Sasaki S, Kondo T, Sata F, et al: Maternal smoking during pregnancy and genetic polymorphisms in the Ah receptor, CYP1A1 and GSTM1 affect infant birth size in Japanese subjects. Mol Hum Reprod 2006; 12: 77–83.
Hayes JD, Pulford DJ : The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 1995; 30: 445–600.
Kim JH, Park SG, Lee KH, et al: GSTM1 and GSTP1 polymorphisms as potential factors for modifying the effect of smoking on inflammatory response. J Korean Med Sci 2006; 21: 1021–1027.
Jones KG, Brull DJ, Brown LC, et al: Interleukin-6 (IL-6) and the prognosis of abdominal aortic aneurysms. Circulation 2001; 103: 2260–2265.
Brull DJ, Montgomery HE, Sanders J, et al: Interleukin-6 gene −174g>c and −572g>c promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler Thromb Vasc Biol 2001; 21: 1458–1463.
Tiret L : Gene-environment interaction: a central concept in multifactorial diseases. Proc Nutr Soc 2002; 61: 457–463.
Bazzano LA, He J, Muntner P, Vupputuri S, Whelton PK : Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States. Ann Intern Med 2003; 138: 891–897.
Albert MA, Danielson E, Rifai N, Ridker PM : Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001; 286: 64–70.
DeMichele A, Martin AM, Mick R, et al: Interleukin-6 −174G→C polymorphism is associated with improved outcome in high-risk breast cancer. Cancer Res 2003; 63: 8051–8056.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Saijo, Y., Yoshioka, E., Fukui, T. et al. Effects of the Interaction between Interleukin-6 −634C/G Polymorphism and Smoking on Serum C-Reactive Protein Concentrations. Hypertens Res 30, 593–599 (2007). https://doi.org/10.1291/hypres.30.593
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.30.593
Keywords
This article is cited by
-
Interactions of genetic and non-genetic factors on plasma hs-CRP concentration in a Korean community-based cohort study
Genes & Genomics (2015)
-
Analyses of longitudinal effects of gene-environment interactions on plasma C-reactive protein levels: the Hallym Aging Study
Genes & Genomics (2013)
-
Inflammation as a cardiovascular risk factor and pulse wave velocity as a marker of early-stage atherosclerosis in the Japanese population
Environmental Health and Preventive Medicine (2009)